-
Technology
-
Industry
-
Solutions
-
- ASSET MANAGEMENT
- CUSTOMER EXPERIENCE MANAGEMENT
- CYBER SECURITY
- DATA CENTER
- DOCUMENT MANAGEMENT
- ELECTRONIC DATA INTERCHANGE
- ENTERPRISE DATA MANAGEMENT
- ENTERPRISE RESOURCE PLANNING
- ENTERPRISE RISK MANAGEMENT
- ENTERPRISE-GRADE WEB DATA SOLUTIONS
- FACILITY MANAGEMENT
- FIELD SERVICE
- IDENTITY AND ACCESS MANAGEMENT
- INFRASTRUCTURE
- IT SERVICE MANAGEMENT
- MANAGED IT SERVICES
- PAYMENT AND CARD
- PROJECT MANAGEMENT
- SOFTWARE TESTING
- STORAGE
- VIDEO SOLUTIONS
- WORKFLOW
-
-
Platforms
-
Functions
- Leadership Perspectives
- Innovation Insights
- Research
- Magazines
- News
- CXO Awards

SEATTLE, WA: CMC Biologics, process developer and manufacturer of biopharmaceuticals signs agreement with River Vision Development Corporation (River Vision), a company focused on ophthalmology, for process transfer and cGMP production of RV001(Teprotumumab)- a recombinant monoclonal antibody targeting insulin-like growth factor 1 that is under development for treatment of Grave’s Orbitopathy and other indications. Grave Orbitopathy is autoimmune inflammatory disorder affecting the orbit around eyes such as swelling, redness, conjunctivitis and bulging of eyes.